Clinical Trial Search

Primary: Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment — 32 participants

Primary: Number of Participants With Adverse Events That Are >= Grade 4 According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)…

Primary: The First Day on Which Patients Are Free From Symptoms of Phototoxicity Following Phototesting

Primary: Safety: Number of Participants With at Least One Adverse Event — 10 Participants — p=<0.05

Primary: Response Rate

Primary: MTD of Photodynamic Therapy — 150 J/cm^2

Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001

Primary: Number of Participants With Histologically Confirmed Complete Response — 25; 11 Participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Tumor Clearance Rate Following Red or Blue Light PDT — 87.3; 99 Percentage of tumors cleared

Primary: Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months — 5.9; 7.6; 16.4 Letters

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants

Primary: Blanching of Port Wine Stain Birthmark — 16 participants

Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit

Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions

Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001

Primary: Change in Lesion Counts in 25 cm2 Target Area Relative to Baseline. — -72; -37.5 lesions

Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses

Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants

Primary: Assessment of Baseline-adjusted Plasma Concentration-time Curves for ALA After a Single PDT Treatment Applying 3 Tubes of BF-200 ALA in Conjunction With the BF-RhodoLED®…

Primary: Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an…

Primary: Treatment Efficacy Based on Participant AK Lesion Clearance — 59; 34; 43; 76 percentage of AK lesions

Primary: Change in Treatment Symptoms — 3.9; 0.5; 0.37 score on a scale

Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001

Primary: Change in Inflammatory Lesion Counts Relative to Baseline — -18.0; -14.0; -19.0; -14.5 change in lesion count — p=0.7680

Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions

Primary: Actinic Keratoses Reduction Percent — 71.4; 80.2; 72.5; 68.3 percentage

Primary: Complete Clearance (%) of Actinic Keratoses (AKs) — 81; 60 percentage (%) of AK clearance

Primary: Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor — 3; 0; 1; 1 Participants